capabilities
Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation
This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.
Advancing Aseptic Manufacturing: GRAM’s Vision for the Future of Sterile Drug Production
Aseptic manufacturing , Isolator technology, Automation and robotics, Flexible fill-finish capabilities, Advanced drug delivery systems, Regulatory compliance (Annex 1), Strategic partnerships, Patient-centric solutions
FogPharma Rebrands to Parabilis Medicines, Emphasizing AI-Driven Drug Discovery
FogPharma, Parabilis Medicines, AI capabilities, drug discovery, rebranding
BIOSECURE Act: Navigating Industry Implications and Future Directions
BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience